Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Tumor tissues often experience hypoxia owing to accelerated
2024-09-13

Tumor tissues often experience hypoxia owing to accelerated growth rates of malignant cells, accumulation of metabolic products, disorganization of tumor blood vessels, and high interstitial fluid pressures (Makino et al., 2001). In response to AAD treatment, tumor vascular density often decreases t
-
br Eprosartan The AT R antagonist eprosartan is approved
2024-09-13

Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential salicin and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events, indepe
-
Of the cardiovascular studies involving ARBs reported renal
2024-09-13

Of the cardiovascular studies involving ARBs, 3 reported renal outcomes. In the Losartan Intervention For Endpoint study, albuminuria was observed less frequently in the losartan than in the atenolol arm (7% vs. 13%; p=0.002) (5). In the Candesartan Antihypertensive Survival Evaluation in Japan tri
-
The most common adverse effects
2024-09-13

The most common adverse effects were ARIA, which occurred at higher levels than in any previous anti-Aβ mAb study. ARIA-E was observed at some point during the trial in no participants in the placebo group compared with 1 (3%), 2 (6%), 11 (37%), and 13 (41%) participants receiving 1, 3, 6, and 10 mg
-
Because of the critical roles
2024-09-13

Because of the critical roles played by AMPK in energy sensing and cancer cell survival, a huge number of drugs have been proposed to exert their pharmacological effects by means of AMPK activation (Kim and He, 2013). For example, metformin has been shown to activate AMPK in muscle (Sajan et al., 20
-
Thieno-GTP Second the phosphorylation events e g Thr and Ser
2024-09-13

Second, the phosphorylation events (e.g., α-Thr172 and β-Ser108) needed for AMPK activation by small molecules binding at the ADaM or other sites remains unclear. Within the β-GBD, phosphorylation of β1-Ser108 was shown to be required for the activation by small molecules binding in the ADaM site, s
-
Based on our findings in this work as well as
2024-09-13

Based on our findings in this work as well as the previous published data in the experimental mice model of RSV infection, we suggest that modulation of 12/15 LOX expression and/or blocking of LOX products such as 12(S)-HETE may represent potential pharmacological approaches to prevent or treat vira
-
There are several strengths and weaknesses of the
2024-09-12

There are several strengths and weaknesses of the current investigation which merit consideration. Obviously, the current findings are important and less prone to bias than findings from traditional observational epidemiological studies, because causal investigations with the use of genetic variants
-
br Concluding Remarks The effects of point
2024-09-12

Concluding Remarks The effects of point mutations of the four ARs on ligand binding affinities, functional potencies, and efficacies constitute a valuable source of pharmacological information. We analyzed the existing data and mapped it on the collection of available AR crystal structures, allow
-
lipid peroxide In this study an in vitro AChE
2024-09-12

In this study, an in vitro AChE inhibition assay combined with UF-HPLC-ESI-Q-TOF/MS method was developed for rapid screening and identification of AChEI from the roots of C. chinensis Franch. Five compounds was found with AChE inhibitory activity and identified by the on-line DAD-ESI-Q-TOF/MS compar
-
br Conflict of interest br Acknowledgments This work
2024-09-12

Conflict of interest Acknowledgments This work was supported by research grant [PR26/20326] from Santander Bank/UCM. The authors would like to thank Miguel Capo, Professor of Toxicology from the Universidad Complutense de Madrid, for his counseling during the preparation of the present work.
-
Molecular docking simulations were carried out
2024-09-12

Molecular docking simulations were carried out for ligands – in the ACE crystal structure (1O86) and DPP4 crystal structure (2G5P). Comparison of the binding mode of – () with enalaprilat (a) in ACE shows that the phenethyl group (–, enalaprilat) occupies the S1 pocket and the adjacent carboxylic br
-
Composite soil samples were transported
2024-09-12

Composite soil samples were transported to the laboratory and then dried, crushed and passed through a 2mm sieve was. Sample digestion and release of elements method Sposito was performed [15]. Accordingly, taking into account soil moisture to 2g soil samples 12.5ml of nitric acid was added 4M. Samp
-
The present study has several limitations First
2024-09-12

The present study has several limitations. First, the results were obtained using RAW264.7 cells, which are derived from BALB/c mice infected with the Abelson leukemia virus (Raschke et al., 1978). However, these cells, which are a commonly used mouse macrophage cell line, show properties similar to
-
br Acknowledgements This work was
2024-09-12

Acknowledgements This work was supported by the FedEx Institute of Technology at The University of Memphis (to DLB and ALP), NSF REU CHE 1156738 (to ALP in support of RSS), and NIHCA921060 (to GT). This material is based upon work supported by the National Science Foundation under Grant No. CHE-1
16015 records 106/1068 page Previous Next First page 上5页 106107108109110 下5页 Last page